Moneycontrol PRO
Upcoming Event:Attend Algo Convention Live, 2 Days & 12+ Speakers at best offer Rs.999/- for Moneycontrol Pro subscribers. Price Increasing Soon!

Sun Pharma, Cipla and others partner to conduct trials of COVID-19 antiviral drug Molnupiravir

As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization, Dr.Reddy’s will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr. Reddy’s in its clinical trial.

June 29, 2021 / 04:48 PM IST
Molnupiravir demonstrated highly promising results in reducing viral load to almost zero in merely 5 days of treatment duration. (Representative image)

Molnupiravir demonstrated highly promising results in reducing viral load to almost zero in merely 5 days of treatment duration. (Representative image)

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

In a first of kind its initiative, five large Indian pharmaceutical companies Cipla, Dr Reddy's, Emcure, Sun Pharma and Torrent Pharma have joined hands to conduct clinical trials of COVID-19 oral antiviral drug Molnupiravir for the treatment of mild COVID-19 in an outpatient setting in India.

As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization, Dr.Reddy’s will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr. Reddy’s in its clinical trial.

The parties will jointly sponsor, supervise and monitor the clinical trial in India.

Following the clinical trial protocol approval given by the Drugs Controller General of India, the clinical trial will be conducted for the treatment of mild COVID-19 in an outpatient setting. It is expected to take place between June and September this year across India with the recruitment of 1,200 patients.

Between March and April this year, these five pharma companies had individually entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
"Such collaboration for a clinical trial is a first of its kind within the Indian

pharma industry, and will aim to investigate yet another line of treatment in the collective fight against the COVID-19 pandemic," the five companies said in a joint statement.

On successful completion of the clinical trial, each company will independently approach the regulatory authorities for approval to manufacture and supply Molnupiravir for the treatment of COVID-19 in India.

Molnupiravir is an oral anti-viral that inhibits the replication of multiple RNA viruses including SARS-CoV-2.

It is presently being studied by MSD (Called as Merck in US), through a collaboration with Ridgeback Biotherapeutics, in a Phase III trial for the treatment of non-hospitalized patients with confirmed COVID-19 globally.



Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jun 29, 2021 04:48 pm
Sections
ISO 27001 - BSI Assurance Mark